Atreca, Inc. (BCEL) Stock Plunged 35.57% Today, Here’s Why

Atreca, Inc. (BCEL) stock plummeted 33.48% in the current-market trading session at the price of $3.46 despite no fundamental updates.

BCEL is a biopharmaceutical firm that produces antibody-based therapeutics using its differentiated discovery technology. This platform identifies novel antibody-target pairs developed by the immune system during immune reactions against tumors.

BCEL Scheduled Annual Healthcare Conference

On 4th March 2022, BCEL has scheduled to present in Cowen’s Annual Healthcare Conference held virtually from 7th to 9th March 2022. President and CEO John Orwin will participate in a discussion. The topic for debate is Novel Oncology Targets which will be on Monday, 7th March 2022, from 12:50 to  1:50 p.m. A live webcast will be available at the Events and Presentations section of the Company’s official website.

BCEL Published Q4 2021 Results

On 3rd March 2022, BCEL reported its earnings report for the Q4 and the year ended 31st December 2021. The company has also delivered clinical updates from its ongoing trial of ATRC-101 in solid tumors. As of 31st December 2021, cash and cash equivalents totaled US$148.1M.

BCEL calculated a net loss of US$109.3M, or a loss per share of $2.95, for the year 2021. For the Q4 of 2021, the company has a net loss of US$29.5M or a loss per share of $0.79. For the year ended 31st December 2021, R&D expenses totaled US$78.3M. Research and development expenses were US$22.2M for Q4 of 2021. General and administrative costs totaled US$32.0M for the full year 2021. For Q4 ended 31st December 2021, the company has G&A expenses of US$7.3M.

Management Comments

CEO of BCEL, John Orwin, remarked that 2021 was a highly fruitful year for them regarding the clinical growth of ATRC-101 and the advancement of other pipelines. They are satisfied to publish further results from the ATRC-101 clinical program. The data reveals that the program has a clinical activity that validates the company’s approach to determining potentially beneficial antibodies in oncology. They look ahead to delivering additional data on their EphA2 program in April.

Leave a Comment

Your email address will not be published.